Downregulation of DROSHA : Could It Affect miRNA Biogenesis in Endometriotic Menstrual Blood Mesenchymal Stem Cells?
Ana Clara Lagazzi CressoniLetícia B C PenariolCristiana Carolina PadovanMaristela D OrellanaJulio Cesar Rosa E SilvaOmero Benedicto Poli NetoRui Alberto FerrianiCláudia Cristina Paro de PazJuliana MeolaPublished in: International journal of molecular sciences (2023)
Menstrual blood mesenchymal stem cells (MenSCs) have gained prominence in the endometriosis scientific community, given their multifunctional roles in regenerative medicine as a noninvasive source for future clinical applications. In addition, changes in post-transcriptional regulation via miRNAs have been explored in endometriotic MenSCs with a role in modulating proliferation, angiogenesis, differentiation, stemness, self-renewal, and the mesenchymal-epithelial transition process. In this sense, homeostasis of the miRNA biosynthesis pathway is essential for several cellular processes and is related to the self-renewal and differentiation of progenitor cells. However, no studies have investigated the miRNA biogenesis pathway in endometriotic MenSCs. In this study, we profiled the expression of eight central genes for the miRNA biosynthesis pathway under experimental conditions involving a two-dimensional culture of MenSCs obtained from healthy women ( n = 10) and women with endometriosis ( n = 10) using RT-qPCR and reported a two-fold decrease in DROSHA expression in the disease. In addition, miR-128-3p, miR-27a-3p, miR-27b-3p, miR-181a-5p, miR-181b-5p, miR-452-3p, miR-216a-5p, miR-216b-5p, and miR-93-5p, which have been associated with endometriosis, were identified through in silico analyses as negative regulators of DROSHA . Because DROSHA is essential for miRNA maturation, our findings may justify the identification of different profiles of miRNAs with DROSHA-dependent biogenesis in endometriosis.
Keyphrases
- mesenchymal stem cells
- poor prognosis
- signaling pathway
- stem cells
- bone marrow
- umbilical cord
- healthcare
- cell proliferation
- transcription factor
- metabolic syndrome
- molecular docking
- drug delivery
- epithelial mesenchymal transition
- adipose tissue
- polycystic ovary syndrome
- binding protein
- cancer therapy
- insulin resistance
- cell therapy
- pregnant women
- current status
- gene expression
- pregnancy outcomes
- case control